⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053952 | 0.86 | — | — | |
| SCHEMBL19025613 | 0.84 | GAA (0.35) | — | |
| Hydrochloric Acid SCHEMBL27832717 | 0.84 | POLB (0.36) | — | |
| SCHEMBL23795165 | 0.77 | — | — | |
| SCHEMBL30251693 | 0.72 | — | — | |
| SCHEMBL29098712 | 0.70 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL16051303 | 0.70 | — | — | |
| SCHEMBL6843118 | 0.68 | LMNA (0.41) | — | |
| SCHEMBL2308749 | 0.67 | — | — | |
| SCHEMBL15578097 | 0.67 | DPP4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324863-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | US | disclosed |
| US-11384078-B2 | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| EP-3630771-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | Novartis AG (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018220531-A1 | 5,6-FUSED-BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2018-12-06 | — | — | WO | disclosed |
| EP-3083627-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015095477-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS PROTOZOAN PROTEASOME INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES SUCH AS LEISHMANIASIS | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |